Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

In drug-naïve subjects with type 2 diabetes ... The studies presented thus far therefore suggest that DPP-4 inhibition is an efficient treatment of type 2 diabetes, both as monotherapy and ...

There is also a strong rationale provided to avoid use of sliding-scale insulin and to consider the use of oral agents and ...

For patients with nephrolithiasis, sodium-glucose cotransporter-2 (SGLT-2) inhibitor use is associated with a reducti ...

This combination medication contains pioglitazone, a thiazolidinedione agent and alogliptin, a DPP-4 inhibitor ... who are taking other medications, during pregnancy and breastfeeding.

This combination medication contains alogliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor and metformin ... who are taking other medications, during pregnancy and breastfeeding.

A new study has found that SGLT-2 inhibitor drugs for type 2 diabetes may also reduce the risk of kidney stones and gout. These painful conditions are ...

DPP-4 inhibitors – Inhibiting the enzyme DPP-4 increases the level of hormone GLP-1 to stimulate insulin production and decrease glucose levels. Combination drugs – Combination therapies put multiple ...

which aims to anticipate and mitigate critical U.S. drug shortages of essential medicines through non-profit partnership.... HabitNu, a leader in preventive health, has expanded its Diabetes ...

The legislature’s Education and Culture Committee yesterday said that it would establish an interministerial anti-vaping ...

Achieve Life Sciences, Inc. , a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced ...

IDF creating new Type 2 diabetes guidelines with global experts, focusing on patient-centered care and global accessibility.